Cardiology

US adults show an increase in recreational activity post-COVID-19, but lingering cardiovascular risks from infection highlight the need for ongoing health vigilance.

Due to the lived realities and trajectory of risk throughout their lifetime, researchers believe women require novel approaches in their cardiovascular health care needs.

Episode 4 of Wicked Good Cardiometabolic Chat explores SGLT2 inhibitors and their efficacy beyond diabetes outcomes alone.

Research reveals no significant disparities in cardiovascular disease incidence linked to mental disorders after the COVID-19 pandemic.

FDA approves oral semaglutide for reducing cardiovascular risks in high-risk type 2 diabetes patients, enhancing treatment options and outcomes.

Emerging evidence for finerenone showcases the drug’s impact on heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction.

Amgen launches AmgenNow, which is a new direct-to-patient program that will start with evolucumab.

Investigators examine the effects of combination therapy with metformin combined with sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones.

Bumetanide nasal spray is available in 0.5 mg, which is an alternative to traditional oral and intravenous formulations for outpatient therapies.

In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.

Olezarsen significantly reduces triglycerides and acute pancreatitis events, offering new hope for patients with severe hypertriglyceridemia.

With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.

A real-world study found that semaglutide significantly reduced the risk of major cardiovascular events compared to tirzepatide.

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Investigators find this association primarily affects female patients when compared with male patients.

The FDA removes the prior requirement for a patient who is already diagnosed with a cardiovascular disease.

Investigators found that health care costs rose despite the benefits seen with starting semaglutide for patients with and without diabetes.

Although stroke is not common in pregnancy or childbearing years, pregnancy can increase the risk.

In an exploration of recent mothers across the US, researchers addressed the association of hypertensive disorders during pregnancy with breastfeeding and breastfeeding cessation.

After the certification of a new stroke center in respective communities, researchers compared the stroke outcomes of Black patients with those of White patients.

In the study, tirzepatide (Mounjaro) improved measures of A1c, weight, renal function, and all-cause mortality.

The updated label removes the requirement that inclisiran should be used on top of or in combination with statin therapies.

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.